CDSCO Tightens Post-Marketing Drug Safety: PSUR Timelines Now Count from Market Launch, Not Approval Date

Published: May 12, 2026

NEW DELHI — India’s apex drug regulator has officially reset the clock on how pharmaceutical companies track and report the safety of new medicines. In a significant regulatory shift announced on April 21, 2026, the Central Drugs Standard Control Organisation (CDSCO) issued an advisory directing all manufacturers and importers to align their Periodic Safety Update Report (PSUR) timelines with the actual market launch date of a product, rather than the date it received regulatory approval.

This move aims to close a critical gap in the nation’s pharmacovigilance framework. By synchronizing safety reporting with real-world patient exposure, the CDSCO intends to ensure that the most vulnerable early months of a drug’s commercial life are under active, systematic surveillance.

Closing the “Blind Spot” in Drug Monitoring

Periodic Safety Update Reports (PSURs) are the backbone of post-marketing surveillance. They are comprehensive documents that pharmaceutical companies must submit to regulators, summarizing any side effects or safety concerns reported by doctors and patients globally.

Under the New Drugs and Clinical Trials Rules (NDCT), 2019, companies are generally required to submit these reports every six months for the first two years after a drug enters the market, followed by annual reports for the subsequent two years. However, a loophole had emerged: many companies began their reporting cycles the moment they received “paper approval” from the regulator.

If a drug faced delays in manufacturing, pricing negotiations, or distribution, months or even years could pass before the first patient actually took the pill. By the time the drug finally hit pharmacy shelves, the most intensive “six-month” monitoring windows—as dictated by the approval date—had often already expired.

“The gap between approval and launch can be substantial, and during that time, early safety signals may be missed if reporting starts from the wrong date,” explains Dr. Animesh Ray, a pharmacovigilance consultant and former industry safety officer. “This change makes the monitoring window clinically relevant instead of administratively convenient.”

Why the First Months of Launch are Critical

While clinical trials are rigorous, they typically involve a few thousand participants who are closely monitored under “perfect” conditions. Once a drug is launched, it is used by millions of people who may have multiple chronic conditions, take other medications, or fall outside the age ranges studied in trials.

The CDSCO’s new directive ensures that the “intensive monitoring phase” captures this diverse, real-world data. This allows regulators to:

• Identify Rare Side Effects: Some adverse reactions only appear in one out of every 50,000 patients—numbers rarely reached in pre-approval trials.

• Monitor Drug Interactions: Seeing how a new medicine interacts with common treatments for diabetes or hypertension in the general population.

• Update Warning Labels: If a pattern of side effects emerges, the CDSCO can mandate faster updates to the “Patient Information Leaflet” to protect the public.

Dr. Shalini Singh, a clinical pharmacologist and public health researcher who has worked with the Pharmacovigilance Programme of India (PvPI), notes that this is the “second line of defense.” According to Dr. Singh, “Better-timed PSURs mean regulators can act sooner when a pattern of unexpected events emerges, which ultimately protects more patients.”

Challenges for the Pharmaceutical Industry

The shift is not without its operational hurdles. For pharmaceutical companies, the April 2026 advisory requires an immediate audit of their current portfolios.

1. Reporting Alignment: Firms that have already filed early PSURs based on approval dates may now need to re-align their schedules and potentially submit “catch-up” reports to ensure the first two years of actual market presence are fully covered.

2. Resource Pressure: Smaller manufacturers with limited safety teams may face an increased workload as they must now monitor data from the very first week of launch with heightened frequency.

3. Data Quality: Industry observers have noted that shifting the start date is only effective if the quality of data remains high. An anonymous senior pharmacovigilance manager at a multinational firm cautioned, “The intent is good, but the real-world impact will depend on how rigorously the PvPI and CDSCO review these reports and push back if the quality slips.”

What This Means for Patients and Doctors

For the average consumer, this change happens “under the hood” of the healthcare system, but it strengthens the safety net protecting them. If you are prescribed a medication that has been recently launched (post-2025), you can have greater confidence that the regulator is receiving fresh, timely data on how that drug is performing in the real world.

Advice for Patients

Health-literacy experts recommend that patients taking new medications take a proactive role in this ecosystem:

• Keep Records: Maintain a simple log of the medicine’s name, dose, and the date you started treatment.

• Report Concerns: If you experience an unexpected side effect, do not just stop the medication. Report it to your doctor or directly to the PvPI helpline at 1800-180-3024.

• Stay Informed: Check for updated labels or “Dear Healthcare Professional” letters that may provide new guidance on how to take the drug safely.

Advice for Healthcare Providers

Doctors and pharmacists are the “eyes and ears” of the CDSCO. With the reporting clock now tied to the launch date, the initial 24 months of prescribing a new drug are the most vital for data collection. Promptly reporting even “suspected” adverse reactions is essential for the success of this new regulatory directive.

Looking Forward

The CDSCO’s directive is part of a broader evolution of India’s drug safety infrastructure. As India continues to grow as a global pharmaceutical hub, aligning its post-marketing surveillance with international best practices is vital. Moving forward, experts expect the CDSCO to increasingly use this aggregated PSUR data to conduct “Signal Reviews”—targeted investigations into specific drugs to ensure that their benefits always outweigh their risks.

References

• Economic Times. “Drugmakers must report safety data from launch date, not approval date: CDSCO.” Published May 10, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.